Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Tibet Rhodiola Pharmaceutical Holding Co has a Sloan Ratio of 11.74%, indicating there is a warning stage of accrual build up.
Tibet Rhodiola Pharmaceutical Holding Co Sloan Ratio % Related Terms
Tibet Rhodiola Pharmaceutical Holding Co Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co Sloan Ratio % Chart
Tibet Rhodiola Pharmaceutical Holding Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co Sloan Ratio % vs Drug Manufacturers Industry
Tibet Rhodiola Pharmaceutical Holding Co Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Tibet Rhodiola Pharmaceutical Holding Co's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 157.21127761 (Sep. 2025 ) + 220.91100201 (Dec. 2025 ) + 302.49446854 (Mar. 2026 ) + 314.1299512 (Jun. 2026 ) = ¥995 Mil.
Tibet Rhodiola Pharmaceutical Holding Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 117.09294416 (Sep. 2025 ) + 297.86375559 (Dec. 2025 ) + 388.7228706 (Mar. 2026 ) + 110.43331599 (Jun. 2026 ) = ¥914 Mil.
Tibet Rhodiola Pharmaceutical Holding Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -206.51225001 (Sep. 2025 ) + 5.3097844 (Dec. 2025 ) + -378.0518204 (Mar. 2026 ) + -96.25929811 (Jun. 2026 ) = ¥-676 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a Sloan Ratio % of 11.74% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors.
Is Tibet Rhodiola Pharmaceutical Holding Co's Sloan Ratio % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current Sloan Ratio % is 11.74%. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's Sloan Ratio % compare to ZTS?
Tibet Rhodiola Pharmaceutical Holding Co's Sloan Ratio % of 11.74% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. Tibet Rhodiola Pharmaceutical Holding Co's current Sloan Ratio % is 11.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥39.85, compared to a current price of ¥36.42 — trading 8.6% below its estimated fair value. The current Sloan Ratio % is 11.74%. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current Sloan Ratio % is 11.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued.
The current stock price of ¥36.42 is trading 8.6% below its estimated GF Value™ of ¥39.85.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
Sloan Ratio %: 11.74%
GF Value™: ¥39.85 vs. price of ¥36.42 (8.6% below fair value)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
93GF Score
Get the complete analysis for SHSE:600211
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
